A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes

Hyejin Lim, Yu Mi Lim, Kook Hwan Kim, Young Eui Jeon, Kihyoun Park, Jinyoung Kim, Hui Yun Hwang, Dong Jin Lee, Haushabhau Pagire, Ho Jeong Kwon, Jin Hee Ahn, Myung Shik Lee

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Autophagy is a critical regulator of cellular homeostasis, dysregulation of which is associated with diverse diseases. Here we show therapeutic effects of a novel autophagy enhancer identified by high-throughput screening of a chemical library against metabolic syndrome. An autophagy enhancer increases LC3-I to LC3-II conversion without mTOR inhibition. MSL, an autophagy enhancer, activates calcineurin, and induces dephosphorylation/nuclear translocation of transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy gene expression. MSL accelerates intracellular lipid clearance, which is reversed by lalistat 2 or Tfeb knockout. Its administration improves the metabolic profile of ob/ob mice and ameliorates inflammasome activation. A chemically modified MSL with increased microsomal stability improves the glucose profile not only of ob/ob mice but also of mice with diet-induced obesity. Our data indicate that our novel autophagy enhancer could be a new drug candidate for diabetes or metabolic syndrome with lipid overload.

Original languageEnglish
Article number1438
JournalNature communications
Volume9
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Autophagy
Medical problems
mice
regulators
Inflammasomes
Lipids
lipids
Calcineurin
Nutrition
Gene expression
obesity
biological evolution
homeostasis
diets
Screening
Transcription Factors
gene expression
Chemical activation
Throughput
clearances

All Science Journal Classification (ASJC) codes

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Lim, H., Lim, Y. M., Kim, K. H., Jeon, Y. E., Park, K., Kim, J., ... Lee, M. S. (2018). A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes. Nature communications, 9(1), [1438]. https://doi.org/10.1038/s41467-018-03939-w
Lim, Hyejin ; Lim, Yu Mi ; Kim, Kook Hwan ; Jeon, Young Eui ; Park, Kihyoun ; Kim, Jinyoung ; Hwang, Hui Yun ; Lee, Dong Jin ; Pagire, Haushabhau ; Kwon, Ho Jeong ; Ahn, Jin Hee ; Lee, Myung Shik. / A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes. In: Nature communications. 2018 ; Vol. 9, No. 1.
@article{e73169fe04904f09b2eaf142567fa2e3,
title = "A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes",
abstract = "Autophagy is a critical regulator of cellular homeostasis, dysregulation of which is associated with diverse diseases. Here we show therapeutic effects of a novel autophagy enhancer identified by high-throughput screening of a chemical library against metabolic syndrome. An autophagy enhancer increases LC3-I to LC3-II conversion without mTOR inhibition. MSL, an autophagy enhancer, activates calcineurin, and induces dephosphorylation/nuclear translocation of transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy gene expression. MSL accelerates intracellular lipid clearance, which is reversed by lalistat 2 or Tfeb knockout. Its administration improves the metabolic profile of ob/ob mice and ameliorates inflammasome activation. A chemically modified MSL with increased microsomal stability improves the glucose profile not only of ob/ob mice but also of mice with diet-induced obesity. Our data indicate that our novel autophagy enhancer could be a new drug candidate for diabetes or metabolic syndrome with lipid overload.",
author = "Hyejin Lim and Lim, {Yu Mi} and Kim, {Kook Hwan} and Jeon, {Young Eui} and Kihyoun Park and Jinyoung Kim and Hwang, {Hui Yun} and Lee, {Dong Jin} and Haushabhau Pagire and Kwon, {Ho Jeong} and Ahn, {Jin Hee} and Lee, {Myung Shik}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-03939-w",
language = "English",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

Lim, H, Lim, YM, Kim, KH, Jeon, YE, Park, K, Kim, J, Hwang, HY, Lee, DJ, Pagire, H, Kwon, HJ, Ahn, JH & Lee, MS 2018, 'A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes', Nature communications, vol. 9, no. 1, 1438. https://doi.org/10.1038/s41467-018-03939-w

A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes. / Lim, Hyejin; Lim, Yu Mi; Kim, Kook Hwan; Jeon, Young Eui; Park, Kihyoun; Kim, Jinyoung; Hwang, Hui Yun; Lee, Dong Jin; Pagire, Haushabhau; Kwon, Ho Jeong; Ahn, Jin Hee; Lee, Myung Shik.

In: Nature communications, Vol. 9, No. 1, 1438, 01.12.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes

AU - Lim, Hyejin

AU - Lim, Yu Mi

AU - Kim, Kook Hwan

AU - Jeon, Young Eui

AU - Park, Kihyoun

AU - Kim, Jinyoung

AU - Hwang, Hui Yun

AU - Lee, Dong Jin

AU - Pagire, Haushabhau

AU - Kwon, Ho Jeong

AU - Ahn, Jin Hee

AU - Lee, Myung Shik

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Autophagy is a critical regulator of cellular homeostasis, dysregulation of which is associated with diverse diseases. Here we show therapeutic effects of a novel autophagy enhancer identified by high-throughput screening of a chemical library against metabolic syndrome. An autophagy enhancer increases LC3-I to LC3-II conversion without mTOR inhibition. MSL, an autophagy enhancer, activates calcineurin, and induces dephosphorylation/nuclear translocation of transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy gene expression. MSL accelerates intracellular lipid clearance, which is reversed by lalistat 2 or Tfeb knockout. Its administration improves the metabolic profile of ob/ob mice and ameliorates inflammasome activation. A chemically modified MSL with increased microsomal stability improves the glucose profile not only of ob/ob mice but also of mice with diet-induced obesity. Our data indicate that our novel autophagy enhancer could be a new drug candidate for diabetes or metabolic syndrome with lipid overload.

AB - Autophagy is a critical regulator of cellular homeostasis, dysregulation of which is associated with diverse diseases. Here we show therapeutic effects of a novel autophagy enhancer identified by high-throughput screening of a chemical library against metabolic syndrome. An autophagy enhancer increases LC3-I to LC3-II conversion without mTOR inhibition. MSL, an autophagy enhancer, activates calcineurin, and induces dephosphorylation/nuclear translocation of transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy gene expression. MSL accelerates intracellular lipid clearance, which is reversed by lalistat 2 or Tfeb knockout. Its administration improves the metabolic profile of ob/ob mice and ameliorates inflammasome activation. A chemically modified MSL with increased microsomal stability improves the glucose profile not only of ob/ob mice but also of mice with diet-induced obesity. Our data indicate that our novel autophagy enhancer could be a new drug candidate for diabetes or metabolic syndrome with lipid overload.

UR - http://www.scopus.com/inward/record.url?scp=85045523997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045523997&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-03939-w

DO - 10.1038/s41467-018-03939-w

M3 - Article

C2 - 29650965

AN - SCOPUS:85045523997

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1438

ER -